Every DEF 14A that SCWORX CORP (WORX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow WORX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full WORX filings page.
SCWorx Corp. is asking shareholders to approve corporate matters at its Annual Meeting on July 22, 2026, including election of four directors, ratification of Astra Audit & Advisory, LLC as auditor, an advisory vote on executive compensation, and authorization for a possible reverse stock split in the range of 1-for-1.5 to 1-for-20.
The proxy states there were 1,066,918 shares of Common Stock and 39,810 shares of Series A Preferred Stock (convertible into 75,915 common shares) outstanding as of the record date of June 9, 2026. The Board may effect a reverse split if it determines it is needed to meet Nasdaq minimum bid requirements.
SCWorx Corp. is asking shareholders at its July 22, 2026 annual meeting to elect four directors, approve executive pay on an advisory basis, ratify Astra Audit & Advisory as auditor for 2026, and authorize a potential reverse stock split.
The reverse split, at a ratio between 1‑for‑1.5 and 1‑for‑10, would be used on an “as needed” basis to help lift the share price to at least $1.00 and support efforts to regain a Nasdaq Capital Market listing. SCWorx currently has 1,066,918 common shares and 39,810 Series A preferred shares outstanding as of June 9, 2026, with each common and as‑converted preferred share entitled to one vote.
SCWorx Corp. filed its definitive proxy for the annual meeting on December 8, 2025. Shareholders will vote on four director seats, an advisory say-on-pay, and ratifying Astra Audit & Advisory as auditor.
The proxy seeks approvals that enable significant financing activity. Proposal 4 asks to approve the issuance of shares upon exercise of January 2025 Private Investment Warrants with a $0.3496 exercise price and 4.99%/9.99% ownership caps, citing Nasdaq Rule 5635(d); the company notes potential cash proceeds if exercised for cash and warns of material dilution. Proposal 5 covers a September 2025 warrant inducement: holders exercised 2,064,000 existing warrants at $0.3496 and received 4,128,000 reload warrants at $0.31004, exercisable after shareholder approval.
Proposal 6 requests pre-approval for a potential $1.5 million future notes-and-warrants financing, with up to 6,250,000 conversion shares and warrants initially exercisable for up to 30,000,000 shares, subject to anti-dilution features. Proposal 7 seeks to increase authorized common shares from 45,000,000 to 150,000,000. Proposal 8 asks to adopt a 2025 Equity Incentive Plan reserving 10,000,000 shares. Record date is October 10, 2025; 12,105,650 common shares were outstanding, plus 39,810 Series A Preferred (1,138,730 as-converted voting shares).